The DIABLO knockout HGC-27 polyclonal cells are a CRISPR/Cas9-edited polyclonal population derived from the human gastric adenocarcinoma line HGC-27, featuring targeted disruption of the DIABLO gene. This loss-of-function model preserves the genetic heterogeneity inherent to the polyclonal format, avoiding clonal selection biases and offering a more physiologically relevant system for studying DIABLO-dependent phenotypes.
HGC-27 is a poorly differentiated gastric adenocarcinoma cell line originally established from a lymph node metastasis of a gastric cancer patient. Widely used to model gastric cancer progression, metastasis, and therapy resistance, this cell line exhibits an adherent, epithelial-like morphology and has been extensively characterized for its responsiveness to chemotherapeutics and death receptor ligands. HGC-27 provides a clinically relevant platform for investigating molecular drivers of gastric carcinogenesis.
DIABLO (SMAC) is a pro-apoptotic mitochondrial protein that, upon apoptotic stimulation, is released to the cytosol where it binds and inhibits IAPs (XIAP, cIAP1/2, survivin). This interaction relieves caspase-9, -3, and -7 from IAP-mediated suppression, triggering apoptosis. DIABLO’s release is governed by upstream regulators including p53, BAX/BAK, and death ligands (TNF-??, TRAIL), and it collaborates with cytochrome c and HtrA2/Omi. The DIABLO-IAP node is a pivotal control point in intrinsic and extrinsic death pathways and is commonly compromised in tumor cells.
In the context of gastric adenocarcinoma, DIABLO disruption is predicted to impair apoptosis by perpetuating IAP-mediated caspase inhibition, mimicking a common survival mechanism in tumors. This polyclonal knockout model allows researchers to investigate how gastric cancer cells bypass cell death upon genotoxic or receptor-mediated stimuli, to evaluate the role of the DIABLO-IAP interaction in drug resistance, and to assess the efficacy of SMAC mimetics in a population with variable DIABLO inactivation.
The DIABLO knockout HGC-27 cells are applicable to apoptosis research, including SMAC mimetic validation, chemosensitivity profiling, and IAP signaling studies. Suitable assays include Western blotting for DIABLO, caspases, and PARP; annexin V/PI flow cytometry; cell viability assays; co-immunoprecipitation of IAP complexes; cytochrome c release measurement; and caspase activity assays. This model supports the development of pro-apoptotic strategies for gastric cancer. For further information or custom solutions, please contact Ascent Research.
